R5XA Stock Chart & Stats
€1.08
-€0.09(-7.69%)
At close: 4:00 PM EDT
€1.08
-€0.09(-7.69%)
Day’s Range― - ―
52-Week Range€0.32 - €1.25
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€54.30M
Enterprise Value€67.22
Total Cash (Recent Filing)€17.08M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Nov 16, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding51,905,796
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.60Price Target Upside140.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Positive EquityA zero debt position and positive equity provide structural balance-sheet flexibility, reducing near-term refinancing pressure and enabling the company to prioritize clinical execution. This lowers insolvency risk over the next several quarters even if operating losses continue.
Clinical Enrollment MomentumClear and accelerating enrollment reduces execution risk for the pivotal NEPHRO study. Strong site activation and KOL support improve the probability of an on‑time top-line readout and subsequent regulatory filing, strengthening the pathway to commercial viability over the medium term.
Cash On Hand Plus Planned TranchesReported cash plus near-term conditional funding, if received, could provide runway through a potential PMA submission. This planned capital structure, contingent on execution, reduces immediate dilution/refinancing urgency and supports continued clinical development.
Bears Say
Minimal Revenue And Large LossesThe company lacks a durable revenue base and exhibits deeply negative margins, meaning operating continuity depends on successful clinical outcomes or external financing. Without commercial products, sustained losses heighten structural funding and scalability risk beyond the next few quarters.
Dependence On Conditional FinancingFunding for the regulatory path is materially contingent on milestone-linked tranches. This ties liquidity to execution and timing; any enrollment delays or missed conditions could force additional dilutive financing or program interruptions, increasing medium‑term execution risk.
Persistent Cash Burn And Rising OpexSustained negative operating cash flow and rising quarter‑to‑quarter operating expenses indicate structural burn. Continued elevated R&D and G&A without revenue generation increases the probability of future funding needs and could compress strategic optionality if clinical or financing milestones slip.
Talphera News
R5XA FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was €0.32 and its highest was €1.25 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is €54.30M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Nov 16, 2026 which is in 93 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on Aug 12, 2026. The company reported -€0.052 earnings per share for the quarter, beating the consensus estimate of -€0.054 by €0.002.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.04.
How many shares outstanding does Talphera have?
Talphera has 51,905,796 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -€0.052 in its last earnings report, beating expectations of -€0.054. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in DE:R5XA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.60 (140.81% Upside)
€2.60 (140.81% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.31%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
R5XA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong clinical and commercial momentum: 75% enrollment in a registrational trial, positive DSMB feedback, KDIGO recognition of nafamostat, expanded market sizing (+21%), and encouraging dosing/titration data. Financially the company has runway assumptions but relies on conditional financing (~$16M) and faces modest near-term expense increases and regulatory timing uncertainty. On balance the achievements and favorable clinical/commercial signals outweigh the financing and timing risks.View all DE:R5XA earnings summariesR5XA Stock 12 Month Forecast
Average Price Target
€2.60
▲(140.81% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
Perrigo Company
―
Organogenesis Holdings
―
Evolus
―
Journey Medical Corp
―